Welcome to our dedicated page for Werewolf Therapeutics SEC filings (Ticker: HOWL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Werewolf Therapeutics, Inc. (Nasdaq: HOWL) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical company developing conditionally activated immune therapies, Werewolf uses its filings to report on financial condition, clinical progress, governance matters, and material corporate events.
Investors reviewing HOWL filings will find Form 8‑K current reports describing key developments such as pipeline and business updates, clinical data summaries for WTX-124 and WTX-330, strategic partnering objectives, and notices related to Nasdaq listing requirements. Results of operations and financial condition for specific quarters are furnished through 8‑K items that reference accompanying earnings press releases and corporate presentations.
Through its periodic reports and exhibits, Werewolf outlines the status of its PREDATOR platform, INDUKINE cytokine prodrugs, and INDUCER T cell engager programs, along with forward-looking statements that detail development timelines, regulatory engagement plans, and cash runway expectations. Governance-related disclosures, including board composition and audit committee matters, also appear in the company’s 8‑K filings.
On Stock Titan, HOWL filings are supplemented with AI-powered summaries that explain the significance of each document in clear language. Users can quickly understand the main points of lengthy filings, identify references to clinical trial updates, partnering strategies, or listing compliance, and navigate to specific sections of interest. Real-time updates from EDGAR help ensure that new filings are surfaced promptly, while access to historical documents allows for analysis of how Werewolf’s clinical pipeline, risk disclosures, and corporate priorities have evolved over time.
Werewolf Therapeutics, Inc. (HOWL)
The group sold 52,627 shares on November 18, 2025 at a weighted average price of $0.93, 66,324 shares on November 19, 2025 at a weighted average price of $0.94, and 41,152 shares on November 20, 2025 at a weighted average price of $0.89. After these sales, they reported indirect beneficial ownership of 5,321,436 shares held across several MPM-managed entities, including MPM Asset Management LLC, MPM BioVentures 2014 funds, MPM Oncology Innovations Fund and UBS Oncology Impact Fund, with each reporting person disclaiming beneficial ownership beyond its pecuniary interest.
Werewolf Therapeutics, Inc. (HOWL) reported insider transactions by entities affiliated with MPM BioImpact LLC, which is identified as a director and 10% owner. Over three days, from 11/18/2025 to 11/20/2025, these reporting persons sold a total of 160,103 shares of common stock in open-market transactions. The weighted average sale prices were around $0.93 on 11/18, $0.94 on 11/19, and $0.89 on 11/20, with detailed price ranges provided for each day. After these sales, the reporting group continued to beneficially own 5,321,436 shares of Werewolf Therapeutics indirectly through multiple affiliated investment vehicles. The filing notes that the trades were executed under a Rule 10b5-1 trading plan dated September 24, 2025.
Werewolf Therapeutics (HOWL) director Luke Evnin reported a series of planned insider stock sales under a Rule 10b5-1 trading plan. On 11/13/2025, affiliated MPM entities sold 58,372 shares of common stock at a weighted average price of $0.98. On 11/14/2025, they sold 39,560 shares at a weighted average price of $0.93, and on 11/17/2025, they sold 36,621 shares at a weighted average price of $0.95. After these transactions, Evnin reported 3,515,880 shares of HOWL common stock beneficially owned indirectly through various MPM investment vehicles. The filing notes that prices are reported as weighted averages for multiple trades within specified price ranges.
Werewolf Therapeutics, Inc. (HOWL) reported insider stock sales by an affiliated director and 10% owner. Investment entities associated with MPM BioImpact LLC filed a Form 4 showing automatic sales of common stock under a Rule 10b5-1 trading plan dated September 24, 2025. On November 13, 2025, they sold 90,951 shares at a weighted average price of $0.98 per share, followed by 61,640 shares at $0.93 on November 14 and 57,061 shares at $0.95 on November 17. After these transactions, the group reported indirect beneficial ownership of 5,481,539 shares held across several MPM-managed funds, while disclaiming beneficial ownership beyond their economic interest. This filing is one of two identical submissions due to limits on the number of reporting persons.
Werewolf Therapeutics, Inc. (HOWL)
On November 13, 2025, the reporting group sold 90,951 shares at a weighted average price of $0.98. On November 14, 2025, they sold 61,640 shares at a weighted average price of $0.93, and on November 17, 2025, they sold 57,061 shares at a weighted average price of $0.95. Each day’s trades occurred across multiple prices within disclosed ranges.
After these transactions, the group reports indirect beneficial ownership of 5,481,539 Werewolf shares held through several affiliated investment vehicles, including MPM Asset Management LLC, MPM BioVentures 2014 funds, MPM Oncology Innovations Fund, and UBS Oncology Impact Fund.
Werewolf Therapeutics (HOWL) — Form 4 insider activity: Director Luke Evnin reported open‑market sales of company common stock executed under a Rule 10b5‑1 trading plan dated September 24, 2025. Sales occurred on four dates: 11/07/2025 (43,950 shares at a weighted average price of $1.11), 11/10/2025 (31,172 at $1.18), 11/11/2025 (35,818 at $1.14), and 11/12/2025 (26,101 at $1.09).
Following these transactions, the reported indirect beneficial holdings were updated to 3,743,524; 3,712,352; 3,676,534; and 3,650,433 shares, respectively. The holdings are indirect through affiliated entities (including AM LLC, BV 2014, BV 2014(B), AM BV2014, and MPM OIF), with a stated disclaimer of beneficial ownership beyond pecuniary interest.
Werewolf Therapeutics (HOWL): affiliated reporting persons led by MPM entities, identified as a director and 10% owner, reported open‑market sales executed under a Rule 10b5‑1 plan dated September 24, 2025. Sales occurred on November 7–12, 2025 across four days totaling 213,529 shares.
Disclosed transactions: 68,480 shares on 11/07 at a weighted average price of $1.11; 48,570 on 11/10 at $1.18; 55,810 on 11/11 at $1.14; and 40,669 on 11/12 at $1.09. Following these trades, the group reported 5,691,191 shares beneficially owned, held indirectly across multiple MPM-managed entities. Price ranges for the weighted averages were provided for each day, and the filing notes it is one of two identical filings due to reporting person limits.
Werewolf Therapeutics (HOWL): A director and 10% owner affiliated with MPM entities reported open‑market sales totaling 213,529 shares across 11/07–11/12/2025 under a Rule 10b5‑1 plan dated September 24, 2025. Weighted average prices by day were $1.11, $1.18, $1.14 and $1.09, with disclosed trade ranges spanning $1.065 to $1.21. Following these transactions, indirect beneficial ownership was 5,691,191 shares.
Werewolf Therapeutics (HOWL) director Luke Evnin reported open‑market sales totaling 155,885 shares on November 4–6, 2025 under a Rule 10b5‑1 trading plan established on September 24, 2025.
Weighted‑average sale prices were $1.22 on Nov 4 (range $1.17–$1.30), $1.22 on Nov 5 (range $1.19–$1.25), and $1.21 on Nov 6 (range $1.185–$1.27). Following these transactions, indirect beneficial holdings were 3,787,474 shares, held across multiple MPM‑affiliated entities. The filing notes the reporting person disclaims beneficial ownership except to the extent of pecuniary interest.
Werewolf Therapeutics (HOWL): Insider transactions disclosed. An affiliated group led by MPM BioImpact reported open‑market sales of common stock on three dates under a Rule 10b5‑1 plan dated September 24, 2025.
Across 11/04/2025, 11/05/2025, and 11/06/2025, the group sold a combined 242,890 shares, at weighted‑average prices of $1.22, $1.22, and $1.21, respectively. Reported price ranges were $1.17–$1.30, $1.19–$1.25, and $1.185–$1.27. Following these transactions, the reporting persons indirectly beneficially owned 5,904,720 shares.
The filing notes the reporting person is a director and 10% owner, and that sales were allocated among affiliated entities including MPM Asset Management LLC, MPM BioVentures 2014, L.P., MPM BioVentures 2014(B), L.P., MPM Asset Management Investors BV2014 LLC, MPM Oncology Innovations Fund, L.P., and UBS Oncology Impact Fund L.P.